PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNews'Personalised' skin cancer drug wins NICE approval

BioNews

'Personalised' skin cancer drug wins NICE approval

Published 19 September 2014 posted in News and appears in BioNews 772

Author

Dr Lanay Griessner

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

A skin cancer drug designed to be effective in patients whose cancer is driven by a specific gene mutation has been recommended by the National Institute for Health and Care Excellence to treat patients with advanced melanoma...

A skin cancer drug designed to be effective in patients whose
cancer is driven by a specific gene mutation has been recommended by the National
Institute for Health and Care Excellence (NICE) to treat patients with advanced
melanoma.

Dabrafenib,
which is marketed as Tafinlar by
GlaxoSmithKline, blocks the growth of cancerous cells containing
the BRAF V600 mutation, which has been linked to half of all aggressive
melanomas.

The mutation, which can be
triggered by ageing and overexposure to the sun, was confirmed in 2009 (see BioNews 503) as the first event in a cascade of genetic changes that
eventually lead to the development of melanoma.

In 2012, NICE recommended two BRAF V600
mutation-targeting drugs: vemurafenib and
ipilimumab (see BioNews 680), after they were shown to improve both quality and quantity of life for certain
patients with advanced melanoma in clinical trials (see BioNews 660).

Professor
Carole Longson, director of the
centre for health technology evaluation at NICE, said: 'Drugs like dabrafenib are thought to have very rapid
positive effect for patients, even in those who are very unwell or bedridden.
In some cases, it has enabled people to resume everyday activities'.

Malignant melanoma is the fifth most
common cancer among 15-to-34-year-olds in the UK and cases have increased by over 50 percent in the last decade. Early
melanomas can often be surgically removed, slowing or halting disease progression, however treatments for
advanced-stage melanoma remain limited.

Dabrafenib is being recommend for advanced-stage patients
who test positive for the mutation and where it is no longer possible to have
the cancer removed surgically.

'While the drug
does not provide a cure, it represents the progress made in our understanding
of biology in advanced skin cancer and how this can be used to develop
innovative treatments to treat the disease', Professor Peter Johnson, Cancer Research UK's chief clinician, told BBC News.

Although the trials of BRAF V600-targeting treatments confirmed
their effectiveness, drug resistance remains a concern in the long run.

Professor
Paul Workman, interim chief executive of the Institute of
Cancer Research in London, said: 'One drawback of dabrafenib and vemurafenib is that
although they are often initially very effective, cancers usually become
resistant to treatment within a year'.

'One very promising area of
our research is the design of so-called panRAF inhibitors, which are intended
to be effective against BRAF and other cancer mutations simultaneously. We hope
that this new type of targeted drug could further expand the currently very
limited treatment options for advanced melanoma'.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 May 2017 • 2 minutes read

Genetic analysis shows progression of moles to melanoma

by Meetal Solanki

Researchers in the USA have mapped the sequence of genetic changes from early skin lesions, such as common moles, to malignant skin cancer...

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family (from Greek and Roman mythology) entwined in coils of DNA.
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family entwined in coils of DNA (based on the figure of Laocoön from Greek and Roman mythology).
News
29 October 2015 • 2 minutes read

US approves modified-virus cancer treatment

by Arit Udoh

The US Food and Drug Administration has approved a drug derived from a genetically modified herpes virus for the treatment of melanoma that cannot be removed by surgery...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
24 August 2015 • 2 minutes read

Precision medicine approach effective in lung cancer

by Kirsty Oswald

Researchers have shown that a skin cancer drug can be used to treat advanced lung cancer in patients whose tumours harbour a particular mutation...

PET BioNews
News
10 April 2015 • 2 minutes read

Personalised cancer vaccines show promise

by Dr Nicoletta Charolidi

A new type of cancer vaccine that enriches the immune system with tailor-made anti-tumour antibodies has shown early signs of promise...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
5 March 2013 • 2 minutes read

Pair of gene-targeted melanoma drugs show promise in late-stage clinical trials

by Dr Tamara Hirsch

Two drugs targeting advanced melanoma linked to a mutation in the BRAF gene are more effective than current chemotherapy at slowing the progress of the skin cancer, clinical trial results indicate...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
31 January 2013 • 2 minutes read

European approval for skin cancer drug that could double lifespan

by Dr Louisa Petchey

The European approval of a new gene-specific drug for an aggressive form of skin cancer marks another step towards an era of personalised medicine. A recent trial showed promising results, with the drug shrinking tumour size and extending life span...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
5 November 2012 • 2 minutes read

Gene mutation melanoma drug recommended for NHS use

by Maria Sheppard

A drug which prolongs life in a form of skin cancer associated with a genetic mutation has been recommended for use on the NHS...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
25 September 2009 • 2 minutes read

New drug targets gene to fight skin cancer

by Lorna Stewart

An early stage trial of a new drug has given hope to skin cancer patients. The phase I trial, the results of which were presented at the European Cancer Organisation and the European Society for Medical Oncology conferences in Berlin, tested the drug PLX4032 for the treatment of advanced metastatic melanoma....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 2 minutes read

UK team identifies genetic flaw that triggers skin cancer

by Dr Will Fletcher

Up to 70 per cent of cases of malignant melanoma, the most deadly form of skin cancer, may be triggered by a mutation in the BRAF gene caused by ageing and over-exposure to the sun. Details of the new findings were published in the journal Cancer Cell...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« 'Angelina Jolie effect' sees breast cancer gene tests double

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Complex structures of the human heart bioengineered

8 August 2022 • 1 minute read

Brain tumour gene also linked to childhood cancers

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856